Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-243 in Adult Solid Tumor and Lymphoma Patients
NCT06223542Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAK-243 in solid tumor and lymphoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
TAK-243
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT06223542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223542.